New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
13:21 EDTINOInovio says ITT analysis achieved statistical significance in VGX-3100 trial
Inovio Pharmaceuticals disclosed in a regulatory filing that it supplemented the information included in its press release issued earlier today about its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18 by announcing through an electronic media statement that per protocol analysis measured subjects who received 3 doses of a 3-dose regimen. "An ITT, or intent-to-treat analysis, also achieved statistical significance," the company stated.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
06:09 EDTINOInovio inititates DNA immunotherapy trial for several types of cancer
Subscribe for More Information
December 17, 2014
08:06 EDTINOInovio appoints Zane Yang as VP, Clinical Development, Oncology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use